Technical Track

In Scope

• Generation of preclinical models to support in vivo or in vitro assessments of target or mutation function (e.g., genetically modified rodents or iPSCs, etc.) of at least 5 targets from the ASAP prioritized list (see Eligible Targets section below).
• Generation of detection reagents to support improved measurement or visualization of the target or target activity (e.g., antibodies, nanobodies, probes) of at least 5 targets from the ASAP prioritized list (see Eligible Targets section below).
• Generation of modulation agents to understand the directionality of therapeutic benefit (e.g., viral vectors, compounds, antisense oligonucleotides, etc.) of at least 5 targets from the ASAP prioritized list (see Eligible Targets section below).

Out of Scope  

• Projects to generate preclinical tools/models for targets outside the list provided by ASAP or projects that will not be generating preclinical tools/models.
• Development of preclinical reagents or models incorporating third-party intellectual property that would prevent or significantly delay distribution.
• Development of preclinical reagents or models that duplicate existing tools or do not provide substantial benefit over alternatives available. 
• Generation of therapeutic candidates or non-preclinical research tools that will remain undisclosed or inaccessible to the research community.
• Generation of target-agnostic devices (e.g., wearable devices, equipment, etc.).

In Scope

• Validation of the tool in appropriate systems (e.g., knockout validation for antibodies, catalytically-dead control for tools towards kinase targets, etc.).
• Characterization of the tool to inform conditions of use in PD research (e.g., application compatibility for antibodies, nigrostriatal system integrity in genetic rodent models, etc.).

Out of Scope 

• Projects performing hypothesis-driven research rather than generating and validating novel preclinical tools/models. Therefore, in-depth mechanistic studies of the target biology, target pathway, or therapeutic potential of the target are out of scope.

In Scope

• Research tools/models must be made available through the commercial repository or academic core represented by the Core/Repository Co-Investigator. This commercial repository or academic core must have a demonstrated history of commercializing research reagents/models. 
• Sales of the research tools at commercially reasonable prices for academic and industry researchers without burdensome licensing requirements for purchasers.
• Established click-to-order e-commerce systems preferred. 

Out of Scope 

• Projects generating preclinical reagents/models that cannot or will not be rapidly shared with the research community through easily accessible mechanisms.
• Solely sharing research tools through MTAs between institutions.
• Proposals to develop a new company or establish a new distribution system.